ChemoCentryx logo
ChemoCentryx CCXI
report update icon

Quarterly report 2022-Q2
added 05-16-2026

ChemoCentryx Net Income | CCXI

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income ChemoCentryx

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
-40.5 M -29.9 M -55.5 M -38 M 17.9 M -40 M -47.3 M -46.9 M -38.7 M -39.9 M -4.62 M -3.1 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
17.9 M -55.5 M -30.5 M

Quarterly Net Income ChemoCentryx

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - -31.7 M -38.6 M -40.5 M -22.3 M -39.2 M -29.7 M -29.9 M -24.1 M 20.3 M -21.7 M -15.5 M -12.9 M -15.2 M -11.9 M -10.8 M -10.9 M -6.87 M -9.42 M 39.7 M -6.56 M -9.24 M -6 M -7.66 M -7.07 M -9.98 M -15.2 M -11.6 M -11.6 M -12.1 M -12 M -12.2 M -10.9 M -12.3 M -11.5 M -9.54 M -9.43 M -9.5 M -10.2 M -9.8 M -10.1 M -10.9 M -9.08 M 18.2 M -8.66 M -7.9 M -6.23 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
39.7 M -40.5 M -12 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
-5.69 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-106 M - - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
-28.5 M - - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
-132 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
-34.4 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
-215 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
-130 M - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
-207 M $ 3.62 4.18 % $ 561 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-7.79 M - 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
-25.5 M - -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
321 M - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
-405 K - -4.36 % $ 27 M usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
-23.4 M - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-252 M - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
-173 M - - $ 69.7 B britainBritain
Avenue Therapeutics Avenue Therapeutics
ATXI
-2.91 M - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
-10.3 M $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
-54.6 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
5 M - 368.57 % $ 41.9 M usaUSA
Atreca Atreca
BCEL
-97.2 M - -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
158 K - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
3.01 M - - $ 109 M usaUSA
Akouos Akouos
AKUS
-86.7 M - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
-223 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
-11.3 M - -8.77 % $ 12.4 M israelIsrael
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
7.05 B $ 59.5 -3.02 % $ 121 B usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
-170 M - - $ 1.41 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
-2.03 M $ 1.1 -1.79 % $ 2.71 B israelIsrael
Iterum Therapeutics Iterum Therapeutics
ITRM
-24.8 M - - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
-12.1 M - -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
-15.2 M - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
-52.5 M - - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
-34.2 M - 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
84.9 M - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-34 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
-241 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
-21.9 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
-41 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
-65.2 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
-43.6 M - - $ 728 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
-142 M - - $ 127 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
-46.4 M - - $ 155 M usaUSA
Aravive Aravive
ARAV
-76.3 M - -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-61.4 M - - $ 231 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-26.2 M - 2.71 % $ 14 M usaUSA
Axcella Health Axcella Health
AXLA
-81.2 M - -16.42 % $ 249 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
27.3 M - - $ 2.02 B usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
-237 M - -0.13 % $ 3.73 B usaUSA
Orgenesis Orgenesis
ORGS
-48.2 M - -33.86 % $ 61.2 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
-152 M - - $ 58.1 M usaUSA